Teva’s low-volume formulation will be a new branded drug, separate from regular Copaxone
What if the new low-volume formulation will be Teva's only version in the market (I assume Teva will switch patients and then withdraw the old product from the market).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.